Announcements Trials
Browse Landscape

Phase

Phase NA 65Phase 2 50Phase 1 12Phase EARLY_PHASE1 10Phase 1/2 10Phase 4 8Phase 3 8Phase 2/3 3

Status

Completed 8Recruiting 5Unknown 3Active not recruiting 3Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 108Thoracic 37Breast 37Other hematologic neoplasm 33Lymphoid 21Genitourinary 18Head & Neck 13Tumor-Agnostic 12Gynecologic 12CNS 10Plasma cell 7Myeloid 7Sarcoma 6Dermatologic 4Other neoplasm 3Endocrine 3Other solid neoplasm 2Other 2Classical hematology 2

Conditions

Pituitary Neoplasms 1Differentiated Thyroid Cancer 1Carcinoma, Neuroendocrine 1

Interventions

toripalimab 1anlotinib 1Temozolomide 1Radiotherapy 1PE regimen 1Fluorouracil 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Endocrine × Clear all
NCT04244708 2020-01-28

The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas

Peking Union Medical College Hospital

Phase 2/3 Unknown
150 enrolled
Endocrine

Pituitary Neoplasms

NCT03992911 2019-06-20

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Peking University

Phase 2/3 Unknown
336 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
113 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡